Business

March 4, 2014

Oxygen Bio shares rise after FDA says development of drug Oxycyte can proceed

Oxygen Biotherapeutics stock rose 14 percent Tuesday after the company announced that federal regulators have lifted their clinical hold on its treatment for traumatic brain injuries.

Related content

Comments

Videos

Editor's Choice Videos